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Abstract 
 
Background: Despite consensus guidelines, only about half of at-risk relatives in families with Hypertrophic 
Cardiomyopathy (HCM) undergo clinical screening and even fewer undergo predictive genetic testing, leaving those 
unscreened at risk for sudden cardiac death. The use of qualitative inquiry to examine family communication and 
complex factors influencing uptake of screening may inform interventions to increase uptake and prevent sudden 
cardiac death. 
Purpose: The purpose of this study was to describe the engagement of at-risk relatives in family screening for 
HCM. 
Specific Aims: The specific aims were to (1) Describe the experience of communication of genetic risk of HCM in 
families with a causative variant for HCM; (2) Use the Theory of Engagement to identify facilitators and barriers to 
family screening in families with a causative variant for HCM; and (3) Identify strategies to increase uptake of 
clinical screening and predictive genetic testing in families with a causative variant for HCM. 
Framework: The Theory of Engagement, adapted from McAllister, was used as an initial framework for the study. 
Methods: A qualitative descriptive design with purposive and snowball sampling was used and data were analyzed 
using qualitative content analysis. 
Results: The overarching theme of Bringing Genetic Risk to the Foreground was comprised of three major themes: 
Cues to Action, Preferences for Knowledge and Gateways to Screening, reflecting factors that affect engagement 
with genetic risk and family screening throughout the lifespan. 
Conclusions: Integrated longitudinal care and access to genetic specialists are needed for patients and families with 
a causative variant for HCM. 
Key Words: Hypertrophic cardiomyopathy, engagement, family screening, qualitative 
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Introduction to the Problem and Specific Aims 
 
Hypertrophic Cardiomyopathy (HCM), a disease of the sarcomere characterized by 
unexplained left ventricular hypertrophy, is the most common inherited cardiovascular disorder, 
affecting at least 1 in 500 individuals in the general population (Maron et al., 1995; Semsarian, 
Ingles, Maron, & Maron, 2015). Although most with this clinically heterogeneous familial 
disease may be without disabling symptoms throughout their lifetime, an important subset 
experience severe sequelae such as heart failure, atrial fibrillation with risk of stroke, and sudden 
cardiac death (SCD) (Ho, 2012). HCM is the most common cause of SCD in the young, 
accounting for approximately one-third of SCD in high school and college athletes in the United 
States (Maron, Doerer, Hass, Tierney, & Mueller, 2009). Although the annual mortality rate 
from HCM is less than one percent per year in the general population (Gersh et al., 2011), SCD 
may be the first manifestation of the disease, with devastating consequences. 
The implantable cardioverter defibrillator (ICD) has been shown to effectively prevent 
SCD in a cohort of high-risk patients with HCM by terminating lethal ventricular arrhythmias at 
a 2-4% appropriate discharge rate per year for primary prevention (O’Mahony et al., 2012). At 
present, the ICD is the only therapy available to prevent SCD and alter the natural history of 
HCM, making family screening of vital importance to identify as many relatives at risk for SCD 
as possible to consider them for ICD implantation. Subsequently, professional societies 
recommend family screening, beginning with clinical screening for risk stratification and 
predictive genetic testing (PGT) once a pathogenic mutation has been identified in the proband to 
exclude at-risk family members who test negative from unnecessary and costly longitudinal 
surveillance (Ackerman et al., 2011; Elliot et al., 2014; Gersh et al., 2011). 
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Despite published consensus guidelines that clearly recommend use of specialized genetics 
services including genetic counseling, uptake (the proportion of those eligible who complete 
clinical screening or PGT) by at-risk relatives in HCM families remains low (See Table 1). Since 
HCM is transmitted in an autosomal dominant fashion, 50% of the patient’s first degree relatives 
(parents, siblings, children) are at risk for the disease which may be present in those without 
symptoms. Failure to engage in clinical screening for HCM leading to potential consideration for 
ICD therapy leaves those at-risk relatives who remain unscreened vulnerable to SCD. 
In studies of facilitators and barriers to uptake in HCM families (See Table 2), commonly 
identified reasons to seek out PGT were ruling out risk for self and children (Khouzam et al., 2014; 
Christiaans et al., 2009; Ormondroyd et al., 2013; Smart, 2010) and relief of uncertainty (Smart, 
2010). Potential barriers to the use of PGT included issues related to communication and family 
responsibility, (Ormondroyd et al., 2013; Smart, 2010), reduced risk perception in the absence of 
symptoms (Ormondroyd et al., 2013), ambivalence about the value of PGT, (Khouzam et al., 2014; 
Ormondroyd et al., 2013; Smart, 2010), anticipated anxiety regarding test results, and issues 
pertaining to access to testing and insurance coverage/discrimination (Khouzam et al., 2014). 
Similar barriers have been reported by those seeking to improve uptake of clinical screening 
without PGT (Finch, Russell, Kumar, and Yousef, 2011; Olaussen et al., 2014). 
Qualitative research, which is designed to capture the human experience related to a 
phenomena of interest via purposive sampling of information rich cases (Sandelowski, 1995), 
can provide valuable contextual information to inform clinical genetics practice (Bernhardt, 
2008). Inviting the voices of patients with variant positive HCM mutations and their at-risk 
relative(s) to be heard will provide further insight into complex, multifactorial issues affecting 
uptake including family responsibility, communication of genetic risk, and disclosure brought to 
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light by previous qualitative (Geelen, Van Hoyweghen, & Horstman, 2010; Ormondroyd et al., 
2013; Smart, 2010; Subasic, 2013) and survey studies (Batte et al., 2015; Christiaans et al, 2009; 
Khouzam et al., 2014). 
To protect patient privacy and autonomy, communication of genetic risk and initial 
recommendations for screening must occur from the proband or index case in the family to their 
at-risk relative(s). The process of engagement, which is defined as “the degree of cognitive and 
emotional involvement with one’s increased risk of developing HCM as a result of one’s family 
history of HCM” (adapted from McAllister, 2003, p. 180) of at-risk relatives has not been well 
described. Further exploration of this experience may lead to increased understanding of 
communication from proband to family members and engagement in screening in HCM families, 
improving uptake and therefore preventing SCD. 
The purpose of this study is to describe the engagement of at-risk relatives in family 
screening for hypertrophic cardiomyopathy. 
The specific aims of the study are: 
 
Aim 1: Describe the experience of communication of genetic risk from the perspective of a) the 
at-risk relative(s) and b) the index case in families with a pathogenic variant for HCM 
Aim 2: Utilize McAllister’s Theory of Engagement to identify facilitators and barriers to 
engagement in family screening for HCM and expand the theory to the HCM population 
Aim 3: Identify strategies to improve engagement in family screening including a) cardiac 
screening and b) predictive genetic testing for families with a pathogenic variant for HCM 
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Background and Significance 
 
Molecular basis of HCM 
Sarcomere mutations cause HCM, which is transmitted in an autosomal dominant pattern, 
with 50% of offspring of an affected individual at risk for inheriting the sarcomere gene mutation 
(Seidman & Seidman, 2011). HCM is characterized by incomplete penetrance, indicating that 
not all individuals who carry the mutation develop the phenotype, and variable expressivity, with 
different clinical manifestations of the disease among patients with the same mutation (Deo & 
MacRae, 2010). Since the discovery of the first mutation of the sarcomere gene in 1990, the 
genetic heterogeneity of the disease has become evident with over 1500 individual mutations 
(90% missense mutations) in 11 or more genes identified (Seidman & Seidman, 2011). The 
majority of mutations involve the cardiac β-myosin heavy chain (MYH7) and cardiac myosin 
binding protein C (MYBPC3) (Ho, 2010). 
Genetic Testing for HCM 
 
Over the past twenty-five years, advances in DNA sequencing have led to commercially 
available DNA testing for HCM beginning in 2003 (Ackerman et al., 2011; Ho, 2012). Over 
time, the cost of commercial testing has decreased and the number of genes covered has 
increased and will likely further expand with whole exome/genome sequencing in the future 
(Judge, 2015). Due to the genetic heterogeneity of HCM, classification of a particular DNA 
variant is probabilistic rather than binary (mutation positive/negative) and variants can be 
reclassified as new information becomes available, which poses a challenge to clinical decision 
making (Ho, 2012). 
Diagnostic or comprehensive genetic testing begins in an initial member of the family 
seeking out genetic services, who is often referred to as the proband or index case – (see Figure 
1) with clinically expressed HCM. Identification of a pathogenic DNA (i.e., disease causing or 
variant) mutation in the proband does not alter medical management, but can aid in differential 
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diagnosis between HCM and other causes of hypertrophy such as hypertension, athlete’s heart, 
and metabolic storage diseases (Ho, 2012). Approximately 50% of genetic tests of the proband 
yield a negative result, and variants of unknown significance (VUS) are reported in about 15% of 
tests (Maron & Maron, 2014). A pathogenic variant is identified in approximately 35% of 
genotyped patients (Maron & Maron, 2014). 
Family members of probands in whom a pathogenic variant has been identified have the 
option of predictive genetic testing (PGT), sometimes referred to presymptomatic genetic testing, 
or cascade screening. In those families where the proband has not had a pathogenic variant 
identified, (negative result or VUS), PGT is not an option and continued clinical surveillance is 
recommended (Ho, 2012). In instances where one or more variants of unknown significance 
have been identified, testing of additional family members (when available) may be suggested to 
look for co-segregation of the variant(s) in those clinically affected (Gersh et al., 2011). 
Currently, the greatest clinical utility of genetic testing for HCM is PGT of pre- 
symptomatic, first degree relatives after testing in the proband confirms a genetic mutation 
(Ingles & Semsarian, 2014). PGT then entails a targeted sequencing of the genes associated with 
the family mutation in these individuals (see Figure 2) (Ingles & Semsarian, 2014). A negative 
result in the at-risk family member spares them a lifetime of continued surveillance in the 
absence of symptoms and the disease is also ruled out in their offspring. A positive mutation 
status in an asymptomatic individual may result in increased surveillance, and where HCM is 
ultimately diagnosed, avoidance of high risk activities (Maron et al., 2015), and risk stratification 
for SCD (Deo & MacRae, 2010). Furthermore, knowledge of mutation status in the at-risk 
relatives can assist in family planning, with the option of pre-implantation genetic testing in 
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embryos created through in vitro fertilization for those who do not wish to pass on the disease- 
causing allele (Ho, 2012). 
Increased availability of and access to genetic testing for HCM has led to identification of 
a new category of patients who are genotype positive but phenotype negative, without evidence 
of left ventricular hypertrophy (Maron & Maron, 2014). Targeted medical therapies to modify 
disease before irreversible structural damage to the heart occurs are currently being tested in 
genotype positive patients prior to diagnosis of clinical disease and represent an innovative 
prospect in treatment enabled by PGT (Ho, Charron, et al., 2015; Ho, Lakdawala, et al., 2015). 
As advances in genetic technology continue to contribute the ultimate goal of prediction and 
prevention of HCM (Ho, 2010), the potential benefits and harm of preclinical disease detection 
should be considered (Ingles, Burns, Barratt, & Semsarian, 2015). 
Clinical Screening 
 
Clinical screening, with or without genetic testing, is a Class I recommendation (should 
be performed) for first degree relatives (i.e., children, siblings, and parents) of patients with 
phenotypic HCM per the American College of Cardiology and American Heart Association 
(Gersh et al., 2011) and the European Society of Cardiology (Elliott et al., 2014). Clinical 
screening for HCM consists of imaging tests (primarily echocardiography) and an 
electrocardiogram in conjunction with a history and physical and three generation family 
pedigree. Suggested criteria for confirmation of phenotypic expression of HCM include an 
unexplained left ventricular wall thickness greater than 15 mm in the absence of a dilated left 
ventricle as visualized by 2D echocardiography (Maron et al., 2014). 
Historically, left ventricular hypertrophy (LVH) in HCM was felt to appear most 
commonly during adolescence but can also appear in infancy or early childhood as well as 
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during later adulthood (Maron et al., 2004). Conversions from normal wall thickness to LVH 
have been described in later adulthood and the variable onset of phenotypic expression 
associated with HCM guide current clinical screening practices (Maron et al., 2004). Recent 
observations in genotyped cohorts have indeed shown that middle age adult onset disease is the 
norm (Page et al., 2012), emphasizing the importance of screening at-risk individuals well into 
adulthood. 
Clinical screening recommendations with ECG and echocardiogram begin at age 12 in 
the absence of other indices of suspicion, and continue every 12 to 18 months until ages 18 to 21, 
after which screening every 5 years is typically recommended (Maron et al., 2004). In instances 
where echocardiogram is inconclusive due to suboptimal imaging, cardiac magnetic resonance 
imaging (CMR) may be used to confirm diagnosis and phenotype (Gersh et al., 2011). There is 
also evidence to suggest that late gadolinium enhancement (LGE) associated with CMR may 
play a role in risk stratification for SCD in HCM patients (Chan et al., 2014). 
An improvement in clinical screening rates for first degree relatives of patients with 
HCM following implementation of a specialized HCM clinic has been reported by Finch, 
Russell, Kumar and Yousef (2011) in the UK and Olaussen et al. (2014) in Australia. Both 
groups identified barriers to clinical screening, including lack of understanding of the mode of 
inheritance, strained family relations, and personal preferences of family members to opt out. 
Finch et al. (2011) also listed geographical and logistical issues as impediments to screening. In 
discussing similar barriers identified by both groups, Olaussen et al. (2014) comment that the 
“paucity of literature explaining barriers to clinical HCM screening rates necessitates inferences 
from other diseases, such as colonoscopies in patients with a family history of colorectal cancer” 
(p. 668). 
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Risk Stratification 
 
The rationale for clinical screening of at-risk relatives of patients with a confirmed 
diagnosis of HCM is to identify family members with undetected disease who are at risk for SCD 
which may occur as the first indication of the potentially lethal disorder. Following clinical 
screening, risk stratification for patients with a confirmed diagnosis of HCM involves identifying 
those at highest risk for SCD, which is most common in individuals under 30 years of age 
(Maron & Maron, 2013). Risk for SCD is comparable in both genders (Olivotto et al., 2005), and 
not particular to race. 
For HCM patients deemed to be at high risk for SCD, implantation of an ICD is the only 
reliable prevention strategy resulting in prolongation of life, with proven efficacy in terminating 
lethal ventricular arrhythmias (Page et al., 2012). Five established risk factors for SCD in HCM 
which inform the decision to implant an ICD are 1) family history of HCM-related SCD; 2) 
unexplained recent syncope; 3) massive LV hypertrophy (≥ 30mm thickness); 4) non-sustained 
VT on serial ambulatory Holter; and 5) hypotensive or attenuated blood pressure response to 
exercise (Ho, 2012). These risk factors and other characteristics to guide decision making such as 
LGE, are used to identify HCM patients who would benefit most from ICD therapy although the 
process remains imprecise, largely due to the low positive predictive value of each risk factor 
(Ho, 2012). 
Communication of genetic risk 
 
Information acquired via clinical screening and genetic testing provided by a genetic 
counselor or clinician confers an estimate of genetic risk that may be communicated from the 
index case to at-risk family members. However, the body of research on communication of risk 
for monogenic cardiovascular disorders is less well established than in other populations where 
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commercial genetic testing has been available for a longer period of time. Systematic reviews of 
studies of communication of genetic risk highlight research conducted primarily in families with 
late onset disorders, including hereditary cancers such as Hereditary Breast and Ovarian Cancer 
and Hereditary Non-Polyposis Colorectal Cancer (Seymour, Addington-Hall, Lucassen, & 
Foster, 2010) and in families with Huntington’s Disease grouped with other hereditary cancers 
and disorders (Gaff et al. 2007; Wiens, Wilson, Honeywell, & Etchegary, 2013; Wiseman, 
Dancyger, & Michie, 2010). 
Descriptive studies of the experience of probands (Gaff, Collins, Symes, & Halliday, 
2005) and both probands and at-risk relatives (Roshanai, Lampic, Rosenquist, & Nordin, 2010) 
around disclosing cancer genetic information cite lack of contact and social and geographical 
distance, in addition to perceptions of irrelevant information ,as barriers to communication. 
Roshanai et al. (2010) speculate that a lack of clear understanding of the genetic information and 
subsequent transfer of the message negatively impact communication, although enhanced 
information at cancer genetic counseling by the same group was not shown to improve 
knowledge, risk perception, or number of relatives informed (Roshanai, Rosenquist, Lampic, & 
Nordin, 2009). Similarly, a communication skills intervention was not shown to affect sharing of 
breast cancer genetic test results (Montgomery et al. 2013), although other genetic counseling 
interventions to improve family communication have been developed (The Socio-Psychological 
Research in Genomics (SPRinG) Collaboration et al., (2015) and are being tested prospectively 
(Hodgson et al., 2014). 
Similar research of other hereditary conditions that differ by age of onset, pattern of 
inheritance, and prognosis is needed (Wiseman, Dancyger, and Michie, 2010). Although HCM 
shares an autosomal dominant inheritance pattern with Hereditary Breast and Ovarian Cancer, 
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Hereditary Non-Polyposis Colon Cancer and Huntington’s Disease, the varied age of onset of 
HCM and the risk of SCD distinguish it from other types of oncogenic and neurodegenerative 
conditions. Therefore, a descriptive study of communication of genetic risk in families with 
HCM will expand the literature in this area. 
The experience of communication of genetic risk in families with HCM has not been 
described in depth, particularly from the perspective of the at-risk relative. In an online survey of 
a national sample of patients with HCM recruited from the Hypertrophic Cardiomyopathy 
Association (HCMA), female gender and higher comprehension of autosomal dominant 
inheritance significantly predicted communication of HCM risk information to 100% of the 
participants’ siblings and children (Batte et al., 2015). Patients cited lack of contact and lack of 
closeness with their relatives as barriers to communication. However, survey data may not 
completely capture the contextual issues surrounding communication of genetic risk in HCM 
families. Further exploration of this experience may inform an intervention tailored to the 
cardiovascular genetic population. 
Nursing Implications 
 
There is a need for further research on the human experience of genetic disorders to 
uncover the complexities of patient and family engagement in the context of family screening. 
As providers of health care, nurses are obligated to understand how to assist the growing number 
of patients and families who receive genetic test results (Hamilton, Bowers, & Williams, 2005) 
and facilitate communication leading to engagement in family screening for genetic 
cardiovascular disease. This focus on health promotion and disease prevention for the client 
(patient, family, community) corresponds with an area of genomic nursing research 
recommended by the Genomic Nursing State of the Science Advisory Panel (Calzone et al., 
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2013). The proposed study is also congruent with suggested research in categories of risk 
assessment, communication, and decision support further delineated by the panel. This research 
will contribute to the advancement of nursing science by extending the Theory of Engagement 
from an oncology population to a cardiovascular population and help to guide future studies, 
thereby assisting in translation of genetics and genomics into health care. 
Theoretical Framework 
 
The Theory of Engagement (McAllister, 2002) will serve as a starting point to guide the 
study by framing the interview questions to explore causal and intervening factors affecting 
engagement, which has been defined as “the degree of cognitive and emotional involvement with 
one’s increased risk of developing HCM as a result of one’s family history of HCM” (adapted 
from McAllister, 2002, p.180). Accordingly, an adapted version of the model (see Figure 3), 
wherein the cancer specific factors have been modified will be used. Following traditional 
content analysis, the theory will serve as the basis for directed content analysis of data to 
compare findings from the HCM population to those from the Hereditary Non-Polyposis Colon 
Cancer population (HNPCC). 
Engagement originated as the core category best suited to describe the data that emerged 
from a grounded theory study of families with HNPCC conducted by UK genetic counselor and 
researcher, Dr. Marion McAllister (McAllister, 2001, 2002). This study was undertaken to 
develop a theoretical model with explanatory power for behavior around predictive genetic 
testing, particularly in high risk families where conventional health behavior models may not 
always apply (McAllister, 2002). McAllister’s model suggests that engagement affects attitudes 
towards PGT (McAllister, 2002). 
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True to the paradigm model of grounded theory (Strauss & Corbin, as cited in McAllister, 
2001), the theory is composed of causal conditions, which are psychosocial factors that facilitate 
engagement, such as being at an age where one’s relative was known to be first affected. On the 
opposite pole there are intervening conditions, which are psychosocial factors that prevent 
engagement or interfere with the impact of causal conditions, such as ignorance of family 
history. Other components in the theory include individual psychological factors such as 
personal theories of inheritance and coping factors which interact with one another and the 
degree of engagement in a recurrent fashion. 
Engagement is the central concept, or hub of the wheel, around which the McAllister’s 
Theory of Engagement is built. McAllister defines engagement as “the degree of cognitive and 
emotional involvement with one’s increased risk of developing cancer as a result of one’s family 
history of cancer” (2003, p. 180). She also delineates partial engagement as “at the cognitive 
level only” and intense engagement as “at cognitive and emotional levels” (2003, p. 180). Since 
engagement at the affective level only was not observed in the study, McAllister posits that 
cognitive engagement is an antecedent of affective engagement. 
McAllister likens disengagement to avoidance/denial and defines it as “no current 
engagement at either cognitive or affective levels” (McAllister, 2002, p. 501). She differentiates 
disengagement from un-engagement, which she explains is when “engagement has not yet 
occurred” (McAllister, 2002, p.496). McAllister defines partial engagement as “thoughts about 
family history of cancer”, and intense engagement as “thoughts and feelings” about family 
history of cancer.” (McAllister, 2002, p.501). She further elaborates that the feelings expressed 
by the intensely engaged include fear and anxiety (McAllister, 2003, p.180). 
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Engagement is depicted on a continuum from un-engagement through partial engagement 
to intense engagement (See Figure 4). When intense engagement is too emotionally painful, such 
as when a participant experiences a family member dying from the disease, disengagement, 
which is reversible, may occur. McAllister postulates that individuals move back and forth 
between varying degrees of engagement along the continuum. She also states that a critical 
degree of engagement (which she acknowledges is not defined in the study) is required for an 
individual to take any action, such as seeking out genetic counseling, undergoing screening, and 
considering PGT. 
The final theory, according to McAllister, is a set of hypotheses about ways in which the 
different components relate or interact around the process of engagement. In her study, 
McAllister (2003) noted an association between the degree of engagement and action in relation 
to cancer risk. She also noted that engagement was a dynamic process that could change over 
time. As HNPCC family members became more aware of their risk, they became more intensely 
engaged. Eventually, intensity of engagement lessened over time, which McAllister 
hypothesized may have occurred after they passed the age at which a family member was 
affected. Those who were intensely engaged prior to predictive genetic testing tended to accept 
mutation carrier status than more readily those who were partially engaged prior to testing. 
Methods 
 
Research Design 
 
A qualitative descriptive design will be used to describe the engagement of at-risk 
relatives in family screening for hypertrophic cardiomyopathy in mutation positive families. 
Qualitative description, which is a form of naturalistic inquiry, provides a data-near, 
comprehensive summary of the phenomena of interest without pre-selection or manipulation of 
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variables (Sandelowski, 2000). The qualitative descriptive design enables the researcher to begin 
with a theory (such as The Theory of Engagement) as a framework for collecting or analyzing 
data, while allowing alternate paths of inquiry as the study unfolds (Sandelowski, 2000). 
Qualitative description is an appropriate design to obtain answers to clinically germane questions 
such as “What reasons do people have for using or not using a service or procedure? Who uses a 
service and when do they use it?” (Sandelowski, 2000, p. 337). 
Population/Setting 
 
Approximately 350 to 400 patients with HCM or those at risk for HCM due to a family 
history of the disease receive longitudinal, comprehensive care by clinicians at the 
Cardiovascular Genetics Center (CVGC) at the study site, which is a major tertiary care facility 
and academic medical center in the Northeast. Specialized care including clinical evaluation, 
treatment, and genetic counseling along with access to advanced imaging, and genetic testing are 
provided at this center. This site has two databases which will be used to select participants. The 
Standardized Clinical Assessment and Management Plan (SCAMP) database was designed by 
the Cardiovascular Genetics Team to optimize patient outcomes and help to identify reasons for 
variation in behavior around utilization of resources. This database tracks the percentage of at- 
risk first degree relatives who have been evaluated by echocardiogram under each index case, 
which could inform maximum variation sampling for the study. The CVGC clinical database 
contains all patients seen at the BWH CVGC clinic, including those not followed longitudinally 
in the SCAMP. 
Sample 
 
Inclusion criteria. Participants are eligible for the study if they meet the following 
criteria: 
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1a. First degree (i.e., parent, sibling, child) (preferentially) or in the absence of first 
degree, second degree relatives (aunt, uncle, niece, nephew, grandparent, half-sibling) of 
patients with a confirmed pathogenic mutation for HCM known for more than three 
months, and 
1b. Patients with a confirmed pathogenic mutation for HCM known for at least three 
months who have at least one first degree at-risk relative (parent, sibling, child) 
preferentially or second degree at risk relative in the absence of first degree (aunt, uncle, 
niece, nephew, grandparent, half-sibling). 
Both patients and at-risk relatives must be: 
 
• Able to speak and read English 
 
• Between the ages of 18 and 65 
 
• Able to provide informed consent 
 
Exclusion criteria. Patients are ineligible for the study if they meet the following 
 
criteria:  
 
• Above index cases without first or second degree relatives 
 
Both patients and relatives are ineligible for the study if they are: 
 
• Under 18 or over 65 years of age 
 
• Unable to speak and read English 
 
• Unable to provide informed consent 
 
 
Procedures 
 
Study approval. Approval from the Institutional Review Board (IRB) at the institution 
will be obtained prior to conducting the study and all participants will undergo informed consent. 
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Federal Health Information Privacy and Accountability Act (HIPAA) standards will be upheld 
throughout the study and the researcher will act responsibly to safeguard sensitive genetic 
information. To maintain confidentiality, data will be coded and de-identified and stored securely 
as detailed in the data management section below. Participants will be made aware of resources 
available to them should they develop any psychological distress as a result of the interview or 
participation in this study. 
Recruitment. The researcher will recruit eligible participants identified in the SCAMP 
and CVGC databases and their first or second degree relatives (in the absence of first degree 
relatives) over an approximate 6 to 9 month period. The researcher will identify potential 
participants via the two databases in conjunction with a CVGC physician or genetic counselor 
and obtain a HIPAA waiver of authorization to access the medical record of these patients to 
obtain their contact information. The researcher will send a letter signed by their CVGC health 
care provider describing the study with the researcher’s contact information should they wish to 
contact the researcher directly or opt out of a recruitment phone call via phone or email. The 
researcher will then follow up each letter to each potential participant (with the exception of 
those who have opted out) with a phone call to describe the study and ask patients for their 
participation. Fliers containing a brief description of the study will also be placed in the CVGC 
clinic. 
Recruitment of first or second degree relatives of the index cases will occur through 
snowball sampling. The investigator will ask the index case participant to identify up to 3 
relatives who might be interested in participating in the study. The index case participant will be 
given study fliers to be distributed to these relatives with the investigator’s contact information. 
The relative can choose to either contact the investigator directly or may ask the index case to 
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provide his/her contact information to the investigator. Additional recruitment sites will be used 
if enough participants are not recruited during the first 6 month time period. Participants will be 
mailed a $25 gift card for taking part in the study. 
Sampling. Purposive sampling from the homogeneous subgroup of mutation positive 
families within the databases will be used to assist in minimizing the number of sampling units 
required to produce analytically meaningful results (Sandelowski, 1995). A maximum variation 
approach (Sandelowski, 1995), will be used to recruit the index cases with the goal of achieving 
demographic variation as well as variation in percentage of family members informed by the 
index case as identified by the SCAMP database. This strategy is designed to seek out 
representative coverage of the phenomena of interest (Sandelowski, 1995). Snowball sampling 
(Creswell, 2013) of the index cases will be used to identify first or second degree relatives for 
participation in the study. A minimum of 20 participants will be recruited (N = 5-8 index case 
participants; N = 12-15 relatives). Recruitment will continue until informational redundancy is 
achieved for both groups. 
Data collection. Following informed consent of the participant, semi-structured 
interviews will be conducted either in person (face to face or via Skype) preferentially or by 
telephone if video conference technology is unavailable, travel distance too long, or per 
participant preference. Flexible interview questions (and open-ended probes) guided by the 
Theory of Engagement will be used as a starting point for the interview. Separate interview 
guides will be used for the index cases and their first or second degree relatives to capture both 
perspectives. Interviews will last approximately 60 minutes and will be audiotaped. Interviews 
conducted via Skype will not be videotaped. 
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Participants will be asked to provide demographic information including age, sex, race, 
ethnicity, socioeconomic status, and time since genetic testing. The researcher will record the 
information manually on the data collection form without use of an audiotape. Three generation 
family pedigrees of the index cases and accompanying clinical notes created by CVGC clinicians 
(genetic counselor and/or MD) will also be obtained via chart review when available. 
As an additional demographic measure, participants will be verbally administered the 
Genetic Literacy and Comprehension Measure (Hooker et al., 2014, with permission), which has 
been adapted from the Rapid Estimate of Adult Literacy in Genetics (REAL-G) (Erby, Roter, 
Larson, & Cho, 2008). The REAL-G has demonstrated strong concurrent validity with the rapid 
estimate of adult literacy in medicine (REALM), and strong predictive validity for patients using 
genetics services (Erby et al., 2007). Educational packets on clinical screening and genetic 
testing given to HCM patients and the link to the Vidscrip (web-based educational video which 
index cases may send via email to their at-risk relatives) will be used to triangulate interview 
data to help establish credibility (Lincoln & Guba, 1985). 
Data analysis. Qualitative content analysis of the interview data with concurrent 
collection and analysis of data will be performed and codes generated from the data 
(Sandelowski, 2000). Content analysis will be carried out in two phases. First, a conventional 
content analysis will be performed to achieve a full description of the phenomena without 
preconceived categories (Hseih & Shannon, 2005). 
Steps for content analysis will be conducted as outlined by Miles, Huberman, and 
Saldana (2014) which include 1) coding of data from various sources; 2) noting insights and 
reflections on the data; 3) sorting through the data to identify similar phrases, patterns, themes, 
sequences and important features; 4) looking for commonalities among the data and selecting 
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them for further consideration and analysis; 5) gradually streamlining the data to a group of 
generalizations that are true for the data; and 6) examining these generalizations in light of what 
is already known. 
In the second phase, a directed content using analysis (Hseih & Shannon, 2005) using 
predetermined codes based on the Theory of Engagement will be performed to validate and 
potentially extend the theory for the HCM population.) If predetermined codes do not fit the 
data, a new category will be assigned. Results will either support or not support applicability of 
the Theory of Engagement to the HCM population (Hseih & Shannon, 2005). To establish 
credibility, negative case analysis (exploring cases that appear to counter the theory) will be 
performed (Lincoln and Guba, 1985). Ongoing peer review and debriefing by a dissertation 
chair/committee will take place throughout the study and a reflexive journal will be kept by the 
investigator cataloging rationale for methodological decisions to maintain an audit trail 
(Creswell, 2013; Lincoln & Guba, 1985). 
Data management. Interview data and field notes will be entered into a Word document 
and demographic data will be entered into IBM SPSS v. 23® Statistics with verification of the 
latter through double entry of data. Each participant’s data will be assigned a code number 
known only to the researcher and only these numbers will appear on data collection forms. All 
paper data will be stored in a locked file cabinet accessible only to the investigator and electronic 
data will be stored on an encrypted, password protected computer on a secure UMMS Research 
drive. All data with patient identifiers will be de-identified prior to entry in a non-Partners 
computer system. 
Limitations 
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The study will be performed in at a single specialized genetics clinic in an academic 
medical center in the Northeast where those who seek care are largely Caucasian, middle to 
upper socioeconomic status, and well educated, which is not necessarily representative of the 
larger population. Since recruitment of at-risk relatives will be done via snowball sampling, 
reaching an adequate sample size to achieve informational redundancy may be problematic. If 
participants are recruited via national support groups outside of the BWH Cardiovascular 
Genetics Clinic, self-reported information will be unable to be confirmed by medical record. 
There may also be sampling bias on the part of the index case to refer those relatives who are 
more likely to be open to participation. The accessible population who agree to participate may 
be more engaged at baseline than those who do not and therefore not representative of the true 
sample. Interviewing by telephone (and to a lesser extent, Skype) limits the researcher’s ability 
to read non-verbal cues. 
Summary 
 
HCM is a clinically and genetically heterogeneous inherited cardiovascular disease which 
may lead to adverse sequelae including SCD in a small subset of individuals, including those 
without symptoms or prior evidence of the disorder. Once a patient is diagnosed with HCM, 
clinical screening of first degree family members, with or without genetic testing, is recommended 
by professional societies to identify as many relatives as possible who may benefit from ICD 
therapy to prevent SCD. However, clinical screening and PGT for HCM in at-risk relatives remain 
underutilized and a deeper understanding of communication between family members and barriers 
and facilitators to family screening, particularly from the viewpoint of the at-risk relatives, is 
needed. A theoretical framework of engagement will be used as a starting point for this qualitative 
descriptive study to describe the engagement of at-risk relatives in family screening with the goal 
ENGAGEMENT IN FAMILY SCREENING FOR HCM   23 
 
of informing development of interventions and future quantitative research for the cardiovascular 
genetic population. 
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Table 1 
 
Studies of Uptake of Genetic Services 
 
Author/Year/ 
Country 
 
Method 
 
Aim 
 
Population/Sample 
 
Uptake 
Factors 
Affecting 
Uptake 
Charron et al. 
(2002) 
 
France 
Observational 
Retrospective 
1. Discuss HCM 
genetic testing 
questions 
 
2. Propose 
guidelines 
 
3. Report on 
preliminary 
experience 
HCM/clinic based 
29 adults with 
pathogenic 
mutation in family 
 
9 sets of parents 
 
22 couples prenatal 
counseling 
 
10 adults for 
diagnostic 
testing 
*19/29 = 
66% for PGT 
adult 
 
1/9 = 
11% for PGT 
child (via 
parents) 
 
*not reported 
as a 
percentage in 
original study 
N/A 
Christiaans et 
al. (2008) 
 
The 
Netherlands 
Observational 
Retrospective 
Assess uptake of 
GC, PGT in HCM 
families within 1 
yr. of 
identification of a 
HCM /clinic based 
 
97 HCM families 
with 
pathogenic 
mutation 
39% for GC 
38.6% for PGT 
99% 
Conditional 
uptake PG 
No difference 
in uptake in GC 
by gender of 
proband or 
relatives, SCD 
in families, or 
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Author/Year/ 
Country 
 
Method 
 
Aim 
 
Population/Sample 
 
Uptake 
Factors 
Affecting 
Uptake 
pathogenic (immediately young age of 
mutation post GC) relative 
Miller et al. Observational 1. Assess uptake HCM/DCM 173/302 = 57% 1st degree 
(2013) Retrospective  of CS and PGT clinic based CS relatives more 
for at-risk 57 probands 84/213 = 39% likely to have 
United States relatives (46 HCM/ 11 DCM) PGT CS and PGT 
2. Test the than 2nd degree 
hypothesis that 40 with pathogenic Comparable to relatives 
uptake of PGT mutation 44% uptake 
similar to other  PGT in HBOC Number of 
genetic 302 relatives for CS population living affected 
conditions 213 relatives for  relatives 
3. Evaluate factors PGT impacted the 
impacting  uptake of CS 
uptake of CS 
and GT among No proband or 
relatives family specific 
factors 
impacted the 
uptake of PGT 
HCM = Hypertrophic Cardiomyopathy; DCM = Dilated Cardiomyopathy; GC = Genetic Counseling; PGT = Predictive Genetic Testing; CS = Cardiac 
Screening; SCD = Sudden Cardiac Death; HBOC = Hereditary Breast and Ovarian Cancer 
 
Table 2 
Qualitative and Survey Studies of HCM families and genetic testing 
 
Author/Year 
Country 
Method 
 
Aim 
 
Population/Sample 
Facilitators 
and Barriers 
to Testing 
 
Themes 
 
Other 
Smart (2010) To investigate 27 participants who Facilitators: N/A Recommendation: 
 the experience had undergone a DNA 1. Reduce   
United of people who test: uncertainty  Facilitate CS by 
Kingdom had been  2. Predict those  identifying ways to 
 offered GT Disorders: at risk,  share information 
Qualitative  HCM (14); LQTS (13) especially  in families and to 
Exploratory   children  support patients 
 Explore Type of Testing:   with family 
 3 key areas: Proband (15) Impediments:  communication 
 Disorders and Cascade (9) 1. Issues of   
 treatment Research (3) communication   
 Genetic  and family   
 testing process Genetic Test Results: responsibility   
 Sharing Pathogenic (17) 2. Ambivalence   
 information in Non-pathogenic (7) around test   
 family groups VUS (3) results   
   3. Burden of 
knowing one is 
at risk for SCD 
  
ENGAGEMENT IN FAMILY SCREENING FOR HCM   34 
 
 
Geelen et al. 
(2011) 
 
The 
Netherlands 
 
Qualitative 
Longitudinal 
To study how 
families deal 
with the 
genetic risk of 
HCM 
6 HCM families 
involved in genetic 
testing followed over 
3.5 years 
 
57 members 
interviewed 
 
Not all relatives 
underwent PSGT 
N/A Key areas: 
 
1. Becoming 
aware of a 
familial 
disease 
2. Making it 
known/ 
disclosure 
3. 
Experiencing 
the family 
disease 
Findings: 
 
Each family 
experienced the 3 
key areas 
according to 
established 
patterns of family 
life which were 
not altered by 
genetic testing or 
HCM diagnosis 
Ormondroyd 
et al. (2013) 
 
United 
Kingdom 
 
Qualitative 
Thematic 
analysis 
1. To explore 
the process of 
PSGT 
2. To 
understand 
how people 
learn about 
risk and make 
decisions re: 
PSGT 
3. To evaluate 
psychosocial 
impact of 
PSGT 
HCM/LQTS 
clinic based 
22 (18 HCM, 4 LQTS) 
> 18 yrs. who had 
undergone PSGT 
since 2004 but not 
within the preceding 
6 months. 
Facilitators: 
Need to know 
for children 
first, then self 
Barriers: 
Low risk 
perception 
(self); 
Insurance, 
Heavy burden, 
Effect on 
marriageability 
(kids) 
N/A Barriers to 
informing family: 
 
Resentment 
Estrangement 
Ambivalence 
about PSGT 
Author/Year 
Country 
Method 
 
Aim 
Population 
Sample 
Facilitators 
and Barriers 
to Testing 
 
Themes 
 
Other 
Subasic 
(2012) 
 
United States 
 
Qualitative 
Phenomeno- 
logical 
Provide an 
insider’s 
account of 
living with 
HCM: 
1. How HCM 
impacts family 
and guides 
15 adults with HCM; 
13 via HCMA 
2 via word of mouth 
45 interviews over 3 
years 
 
7 (46.6%) underwent 
genetic testing but 
 
Facilitator: 
Determine 
future risk for 
children 
 
Barriers: 
 
1. It’s in the 
family 
(disclose?) 
(have GT?) 
 
2. Finding a 
new normal 
 
Diagnostic versus 
predictive genetic 
testing not 
delineated within 
the study 
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Longitudinal decision re: 
GT 
2. How 
physical 
limitations 
associated with 
HCM alter 
being-in-the- 
world 
3. How HCM 
alters social 
relationships 
only 3 (20%) received 
conclusive results 
Financial 
concerns 
Lack of 
awareness re: 
availability of 
GT 
No children 
Not 
recommended 
by MD 
 
 3.HCM and 
relationships 
Christiaans et 
al. (2009) 
 
The 
Netherlands 
 
Questionnaire 
Cross- 
Sectional 
Evaluate 
counselee’s 
views and 
opinions on 
GC PGT, and 
cardiac follow 
up and identify 
associations 
between 
demographics, 
clinical 
characteristics 
and attitude 
towards 
cardio-genetic 
care 
Relatives of 95 HCM 
probands in mutation 
carrying families who 
disclosed DNA test 
results at least 18 
months ago 
 
123/146 who did PGT 
(86% response rate) 
 
76% of carriers 
received regular 
cardiac follow up 
within an avg. time 
span of 3 years post 
test results 
Facilitators: 
Hereditary 
nature of the 
disease 
Need to know 
for self and 
children 
 
Barriers 
(to follow up): 
No symptoms 
Not necessary 
per MD 
Cardiac tests 
normal 
Further research 
needed into why 
some mutation 
carriers not 
receiving regular 
follow up 
 
Carriers who had 
manifest HCM, 
were older and 
male likely to have 
positive attitude 
towards care; 
GC valued 
Ok to receive 
genetic test results 
via phone/mail 
Khouzam et 
al. (2015) 
 
United States 
 
Web-based 
Survey 
Cross- 
sectional 
Uncover 
experience of 
HCM by 
assessing the 
impact of 
select 
demographic 
and familial 
factors, and 
attitudes and 
beliefs toward 
GT on uptake 
306 individuals from 
HCMA diagnosed or 
at risk for HCM 
including those who 
had and had not 
participated in GT 
Facilitators: 
Learn risk for 
family/kids 
Make better 
decisions 
Satisfy 
curiosity 
Provide 
reassurance 
Barriers: 
Insurance 
Access to GT 
Results useless, 
worrisome 
More likely to 
have GT/PGT if: 
 
Offered/discussed 
by clinician 
Saw genetics 
professional for 
HCM 
Professional 
advised testing 
Genetic mutation 
in family 
HCM = Hypertrophic Cardiomyopathy; HCMA = Hypertrophic Cardiomyopathy Association; GC = Genetic Counseling; PGT = Predictive Genetic 
Testing; LQTS = Long QT Syndrome; VUS = Variant of Unknown Significance; PSGT = Pre-symptomatic Genetic Testing; SCD = Sudden Cardiac 
Death 
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Figure 1. Three Generation Family Pedigree (From Cirino and Ho, 2013, with permission) 
 
 
 
 
Figure 1. Pedigree. A pedigree is a family tree. Squares indicate male family members; 
circles, female family members. Solid symbols indicate people who have the family’s disease. 
The arrowhead indicates the proband, that is, the person who is being evaluated for an inherited 
heart disease. His family members are also at risk for developing the condition. The arrows point 
to his first degree family members (children, siblings, parents) who need periodic clinical 
evaluation. 
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Figure 2. Cascade Family Screening (From Cirino and Ho, 2013, with permission) 
 
 
 
Figure 2. Cascade family screening. The circled shapes show family members from 
Figure 1 whose symbols are now darkened because they were diagnosed with heart disease in the 
process of family screening. The arrows point to the first degree family members of all affected 
individuals. These immediate family members need to be examined periodically because they are 
at risk for developing the family’s heart condition. 
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Figure 3. Process of engaging with HCM risk (adapted from McAllister, 2002) 
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Figure 4 
 
Engagement and Action in Relation to Risk (McAllister, 2002, p.497, permission pending) 
 
 
 
 
 
Summary of Changes from Proposal 
The research approach, featuring a qualitive descriptive design using purposive sampling with 
maximum variation of the probands and snowball sampling of the at-risk relatives in families 
with a positive mutation for hypertrophic cardiomyopathy (HCM), was carried out per the 
proposal with the following exceptions:  
1. After the original proposal was submitted which included use of the Standardized 
Clinical Assessment and Management Plan (SCAMP) database in addition to the clinical 
institutional database at the study site, institutional support for the SCAMP was 
withdrawn. This database had been used to track percentage of first degree relatives 
screened and reasons screening had not be completed. Subsequently the researcher lost 
access to this database and relied solely upon the clinical database of patients seen in the 
Cardiovascular Genetics Center (CVGC) at the study site.  
2. After receiving responses from potential participants following recruitment via letter with 
the option to opt out, those interested who met criteria were interviewed after providing 
their verbal informed consent.  To perform subsequent purposive sampling following the 
initial round of interviews, an amendment was filed with the IRB to obtain a HIPAA 
waiver of authorization to view the medical records of patients seen in the CVGC. This 
enabled the researcher to streamline recruitment to those with unscreened at-risk 
relatives.  
3. In the original proposal, second degree relatives were only to be recruited in the absence 
of first degree relatives. In order to be able to interview a second degree relative of a 
proband who already had a first degree relative participating in the study, an amendment 
was filed. This decision was made to pursue an anticipated rich description of a scenario 
where second degree relatives became closer in the context of communication about 
HCM in the family. 
4. In the original proposal, potential participants meeting inclusion criteria were ages 18-65 
years. After subsequent discussion with the content expert on the dissertation committee 
and members of the CVGC group at the study site, a decision was made to change the age 
criteria to 18 years and older. Again this decision was made to pursue the valuable 
experience of older probands and at-risk relatives in the database. 
5. After interviewing the first six participants, it was clear to the researcher that some 
participants had either forgotten information about the genetic component of HCM or had 
limited information. After discussion with the content expert on the committee, a decision 
was made to file an amendment to be able to offer interested participants the email link to 
the Vidscript, a web based educational video about HCM that had been made by genetic 
counselors in the department. If after being told about the Vidscript a participant 
expressed interest, it was sent via email as a follow up to the interview.  
6. In the original proposal, the language “mutation positive” was used to describe the subset 
of HCM patients that would be the focus of the study. After receiving the list of patients 
within the mutation positive subset from the study’s Principle Investigator, letters were 
sent to recruit participants from this list and interviews were conducted. After reviewing 
the charts of some of the participants, it became clearer that the mutation positive subset 
consisted of patients with genetic test results of both “likely pathogenic” and 
“pathogenic” mutations. I later revised the description of the participants to include the 
terms “likely pathogenic” and “pathogenic” to be clearer about the subset.  
7. As per the original protocol, all 29 participants were verbally administered the Genetic 
Literacy Assessment of Comprehension (GLAC) measurement scale at the conclusion of 
the semi-structured interview. However, after multiple unsuccessful attempts to contact 
the researchers who adapted the scale from the Rapid Assessment of Genetic Literacy 
(REAL-G) to obtain permission to use the scale and to gain clarity around proper scoring 
of the scale, a decision was made in conjunction with the dissertation chair to omit the 
GLAC measurement scale results from the manuscript.  
8. After submitting a draft of the results of the study to the content expert on the committee, 
additional information from the medical record was requested for the results such as atrial 
fibrillation and the number of visits the participant had with a genetics MD and genetic 
counselor prior to the time of interview. This information was collected from the medical 
record and added to the results section.  
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Introduction 
• Hypertrophic Cardiomyopathy (HCM) 
• 1 in 500 (~ 600,000 in US) 
• Autosomal dominant 
• Incomplete, age-related penetrance 
• Variable expressivity 
• Sudden cardiac death may be first 
manifestation 
• Consensus guidelines for screening (Gersh, 
2011) 
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Background 
and 
Significance 
• Uptake of family screening for HCM by at- 
risk relatives is low (Miller, Wang and Ware, 2013) 
• Cardiac screening 57% 
• Predictive genetic testing 39% 
• Those unscreened remain at risk for sudden 
cardiac death 
 
 
• Why Aren’t the Guidelines Being Followed? 
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First Step 
Towards 
Family 
Screening 
• Communication of genetic risk to family
members
• Direct contact of at risk relatives prohibited
• Proband as a proxy for genetics clinician
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What is Known: 
Family 
Communication 
of Genetic Risk 
• Oncology and neurodegenerative disease
cohorts
• Contributing factors – Rs and Cs
• In families with HCM
• Follows pre-existing patterns of family
communication
• Female sex and comprehension of
autosomal dominance
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What is Known 
Facilitators and Barriers to Family Screening 
Facilitators 
• Determine future risk for children
• Reduce uncertainty
• Satisfy curiosity, inform decisions
• Recommended by MD
• Saw genetics professional for HCM
• Known family mutation
• Relatives with HCM
Barriers 
• Ambivalence about the DNA test
• Burden of knowing
• Family communication and
responsibility
• Low risk perception
• Insurability and marriageability
• Not recommended by MD
• No children, no access to testing
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Gaps in the 
Literature 
• Few studies of communication of genetic risk
have included families with HCM
• A deeper understanding of the perspectives of
the stakeholders is needed to inform
interventions to increase uptake of family
screening and help prevent sudden cardiac
death
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Theory of Engagement 
(Adapted from McAllister, 2002) 
Definition:
The degree of cognitive and emotional 
involvement with one's increased risk of 
developing HCM as a result of one' family 
history of HCM"
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Purpose 
 
To describe the engagement of at-risk relatives 
in family screening for hypertrophic 
cardiomyopathy 
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1. Describe the experience of communication of 
genetic risk from the perspectives of a) the at-risk 
relatives and b) the probands in families with a 
causative mutation for HCM 
 
 
 
Specific Aims 
2. Use the Theory of Engagement to identify 
facilitators and barriers to family screening for 
HCM and expand the theory to the HCM 
population 
 
3. Identify strategies to improve engagement in 
family screening including a) cardiac screening and 
b) predictive genetic testing in families with a 
causative mutation for HCM 
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Methods 
• Qualitative descriptive design 
• Purposive sampling with maximum variation 
• Snowball sampling of at-risk relatives 
• Partners IRB approval; HIPAA waiver 
• Trustworthiness 
• Peer debriefing and review 
• Analytic and reflexive memoing 
• Triangulation of data 
• Member checking 
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Inclusion 
Criteria 
• Age 18 and over 
• Able to speak and read English 
• Able to provide informed consent 
• First degree relative or second degree relative 
of patients with a causative mutation for HCM 
known for more than 3 months 
• Patients age 18 and over with a causative 
mutation for HCM known for more than 3 
months 
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Sampling and 
Recruitment 
• Institutional database of HCM patients 
• Families with a causative mutation for HCM 
• Letter, followed by phone call 
• Probands identify and reach out to at-risk 
relative with researcher contact info 
• $25 gift card compensation 
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Data Analysis 
• Demographic data: IBM SPSS v. 24®Statistics 
• Audiotaped, transcribed semi-structured 
interviews 
• Qualitative content analysis (Miles and Huberman, 2014) 
• Conventional and directed analyses (Hseih and Shannon, 
2005) 
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Participant Characteristics (N = 29) 
 
 Probands (n=16) At-risk relatives (n=13) Clinical Database 
(N=623)* 
Female (n, %) 10 (62.5%) 8 (61.5%) 242 (38.4%) 
Age in yrs median (range) 57.5 (36-89) 35 (18-74) 48.38 ± 15.90 
White (n,%) 16 (100%) 13 (100%) 448 (81.2%) 
Less than high school 2 (12.5%) 0  
HS/GED/some college 4 (25%) 2 (15.4%) 
4 yr. college or higher 10 (62.5%) 11 (84.6%) 
Relationship to proband   544 (87.3%) probands 
Child … 7 (53.8%)  
Sibling/half-sibling … 6 (46.2%)  
*Database of all HCM pts    
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Clinical Characteristics – HCM Status 
 
 
 
HCM Status Probands (n=13) At-risk relatives (n=16) 
P(+)G(+) 
P(-) G(+) 
P(-) G(-) 
P(+) G unknown 
P(-) G unknown 
LVH G unknown 
 
 
P= Phenotype G=Genotype 
LVH=Left Ventricular Hypertrophy 
16(100%) 3(23.1%) 
3(23.3%) 
1 (6.3%) 
2 (12.6%) 
3 (23.1%) 
1 (6.3%) 
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Clinical Characteristics (N = 29) 
    
Time since diagnosis yrs. 
(median, range) 
15 (7-33) 10 (5-17) 
 
Time since genetic testing yrs. 
(median, range) 
6 (1-11) 6.5 (1-10) 
 
Atrial fibrillation (n,%)  6 (37.5%) 1 (7.7%) 169 (27.1%) 
Current ICD (n,%) 7 (43.8%) 3 (23.1%) 217 (34.8%) 
Heart transplant (n,%) 3 (18.8%) 0 17 (2.7%) 
# CVGC MD/GC visits 
(median, range) 
ICD = Implanted Cardioverter 
Defibrillator; CVGC = 
Cardiovascular Genetics Clinic 
GC = Genetic Counselor 
7.4/1.5 
(1-15/0-2) 
2.1/0.46 
(0-9)/(0-2) 
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Overarching 
Theme and 
Major Themes 
• Bringing Genetic Risk to the Foreground 
• Cues to Action 
• Preferences for Knowledge 
• Gateways to Screening 
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Overarching 
Theme 
Bringing 
Genetic Risk 
to the 
Foreground 
 
 
“Yeah, you bet I did [notify siblings about HCM in 
the family]. Because knowledge is power and 
when I, when I was educated and identified that 
this was, that you could detect this through DNA, 
and really looked at the doctor,…we really looked 
at our family, my family tree and it really became, 
this whole scenario became more in full color for 
me.” (Proband) 
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Major Theme: 
Cues to Action 
• 4 Dimensions: 
• Communication (family, HCPs) 
• Symptoms (family, self) 
• Transition to new life stage 
• Key events 
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Cues to 
Action: 
Key Event 
• “She had it [the DNA kit] on her desk for about 
a year, and I said, ‘When are you going to send 
that in?’ And I think she had some kind of 
mental block about it, but she was visiting up 
here… and she sat down and just flopped back 
her head and I said, ‘Let me have your wrist’ 
and her heart was beating like crazy. And we 
hadn’t been doing anything strenuous…So she 
sent, I guess she…they had to send her a new 
one or something, a new test, but she did send 
it in” (Proband) 
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Cues to 
Action: 
Transition to 
New Life Stage 
• “Yeah, I just think the biggest thing for me really 
is that they’re still treating this disease, or [me] 
with kid gloves in a way because they’re not 
talking about it with me…there’s only so much 
Googling I can do and only so many searches I 
can really do to find out ways I can reduce my 
risk. But I, I would like someone who this is their 
job to talk to me about it, and not just think I’m 
this fragile middle schooler and I care about my 
health and I wanna be proactive.” (At-risk 
relative) 
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Major Theme: Preferences for Knowledge 
 
 
 
• “So, my brother and I, the fact 
that we are able to know that 
there’s a potential for us and 
we’re monitored and people are 
looking out for that specifically 
makes me feel grateful so that 
we’re no one’s surprise ever…” 
(At-risk relative) 
• “Well I think the doctor 
probably suggested it but then 
they both, both my parents 
wanted me to get the genetic 
testing done. Just to know I 
guess…I think I just wouldn’t 
want to know and have it 
hovering over, you know.” 
(At-risk relative) 
ENGAGEMENT IN FAMILY SCREENING FOR HCM   70 
 
 
                                                                                      
ENGAGEMENT IN FAMILY SCREENING FOR HCM   71 
 
 
 
 
 
 
 
 
 
 
 
 
Gateways to 
Screening 
“Um and then recently a couple of years ago, I 
started seeing an [electrophysiologist] and he is 
the one that encouraged me to uh, consider 
genetic testing. And I told him, ‘Well my girls 
had been tested. They’ve had echos and we 
were told we were okay’ And, um, but he, he 
suggested that I, I pursue it.” (Proband) 
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Communication 
of HCM in the 
Family 
• Varied and inconsistent 
• Factors influencing the timing and content of 
the message 
• Understanding of HCM as a genetic 
condition 
• Timing and severity of clinical onset of HCM 
for the proband 
• Age of the at-risk family member 
• Familial culture 
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Discussion: What 
This Study Adds 
• Bringing genetic risk to the foreground –Insight 
into events that shift attentiveness towards 
genetic risk in the HCM population 
• Cues to action - Contextualized information to 
complement results of existing studies 
• Identification of individual, family, provider and 
systems factors for further study/interventions 
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• Bringing genetic risk to the foreground – 
evolving awareness 
 
 
Discussion – 
Comparison to 
What is Known 
• Patterns of “becoming aware of a familial disease” (Geelen 
et al, 2011) 
• Patterns of awareness and disclosure (Atkinson et al., 
• “Foregrounding inherited disease risk” Theory of 
Genetic Vulnerability (Hamilton and Bowers, 2007) 
 
• Cues to action - HCP recommendations 
important (Khouzam et al., 2015) 
 
• Challenges with communication of risk and understanding of 
the spectrum of probability of genetic risk consistent with 
existing literature 
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How Did The 
Theory of 
Engagement 
Work in the HCM 
population? 
• Exemplars of causative and intervening factors 
were identified in the current study population 
• Evidence to support shared phenomena across 
genetic conditions 
• Direct comparison precluded – method, timing 
• HCM specific codes: Fear of sudden cardiac 
death, activity intolerance impacting sports, 
career choices 
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Implications by Theme 
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Further 
Research 
Needed 
• Longitudinal studies using theoretical 
frameworks encompassing the elements of time 
and life stage 
• Family Systems Genetic Illness model 
(Rolland and Williams, 2005) 
• Life Course Perspective (LCP) (Hamilton, 
Innella & Bounds, 2016) 
 
• Experience of genotype positive, phenotype 
negative persons “at-risk population” over the 
life course 
ENGAGEMENT IN FAMILY SCREENING FOR HCM   78 
 
 
 
 
 
 
 
 
 
Further 
Research 
Needed 
• Interventions to assist in education re: 
understanding of basic genetic principles and 
support communication of genetic risk in 
families with HCM 
 
• Experience of communication of risk and 
engagement in family screening for HCM in 
diverse populations 
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Limitations 
• Single academic medical center 
• Caucasian, middle to upper class, well-educated 
• Recall bias 
• Family referral bias 
• No completely unscreened at-risk relatives 
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Conclusion 
• Engagement with genetic risk is a lifelong, 
recursive process. 
• An integrated, longitudinal approach to care 
including appropriate referral and access to 
genetic counseling is needed throughout the 
continuum. 
• Interventions targeting mutable factors such as 
understanding of genetic risk, personal risk 
perception and communication to family are a 
logical next steps to help increase uptake of 
screening. 
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Appendix A 
 
Glowny Interview Guide Index Case 
 
 
Interview Questions 
 
1. Can you tell me how heart disease has 
affected you and your family? 
Probes (as needed) 
 
What is the name of the condition? 
 
Can you tell me more or give me more detail? 
 
What do you understand is the risk of inheriting the 
disease for your siblings, children, parents? 
2. Can you describe how you 
communicated with your relative to 
discuss this heart condition and the 
need for screening? 
What did you tell them? How did you tell them? 
When did you tell them? 
3. Did they have any emotional reactions 
to the discussion? 
 
4. What do you believe were things that 
helped you to discuss the disease with 
your relatives? 
Personal experience of the disease 
Genetic knowledge Family talk Geographical 
distance Family relationships 
Biggest motivation to tell? Did you feel pressure to tell 
them? 
Other important reasons to tell? 
Biggest barrier to communication? Any other 
obstacles? 
5. Have they been screened? 
What tests have they done? 
Echo, ECG, CMR PGT? 
6. Is there anything your health care 
providers could have done to assist 
you in the process of communicating 
with your relatives about the disease? 
More education? 
More psychosocial Support? Other? 
7. I would like to speak to your family 
members too. Is there anyone in your 
family who would be interested in 
speaking with me? Anything you say to 
me will remain confidential. 
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Appendix B 
 
Glowny Interview Guide Relative 
 
 
Interview Questions 
 
1. Can you tell me how heart disease has 
affected you and your family? 
 
2. How did you first learn you were at 
risk? 
Probes (as needed) 
 
What is the name of the condition? 
 
Can you tell me more or give me more detail? 
 
What do you understand is your risk of inheriting 
the disease? 
3. Can you describe how your relative 
told you about this heart condition 
and the need for screening? 
What did they tell you? How did they tell you? 
When did they tell you? 
4. Did you have any emotional reaction 
to the news? 
 
5. What do you believe were things that 
helped you to proceed or not proceed 
with getting screened? 
Personal experience of the disease 
Genetic knowledge Family talk Geographical 
distance Family relationships 
Biggest motivation to get screened? 
Did you feel pressure to get screening? 
Other important reasons to get screening? 
Biggest barrier to getting screening? Any other 
obstacles? 
6. Have you been screened? 
What tests have you done? 
ECG, Echo, CMR, PGT? 
7. Is there anything your health care 
providers could have done to assist 
you in the process of getting screened? 
More Education? 
More Psychosocial Support? Other? 
  
